Nanobiotix Stock Quote NBTX - Stock Price, News, Charts, Message Board, Trades

Level up your trading with our powerful tools and real-time insights all in one place.

Get Started

Home
Investing
Stocks
USA
NASDAQ
Nanobiotix SA (NBTX) Quote

Nanobiotix SA (NBTX)

4.60

-0.75

(-14.02%)

At close: June 14 4:00PM

Delayed by 15 minutes

4.60

0.00

( 0.00% )

After Hours: 4:55PM

Delayed by 15 minutes

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Current Price

4.60

Bid

4.54

Ask

5.25

Volume

20,140

4.60 Day's Range 5.00

0.00 52 Week Range 0.00

Market Cap

Previous Close

5.35

Open

4.95

Last Trade

Last Trade Time

16:25:20

Financial Volume

$ 97,032

VWAP

4.8179

Average Volume (3m)

-

Shares Outstanding

47,133,000

Dividend Yield

-

PE Ratio

-5.01

Earnings Per Share (EPS)

-0.84

Revenue

36.21M

Net Profit

-39.7M

Nanobiotix SA is a clinical-stage biotechnology company that focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. It develops NanoXray products to help patients receiving radiotherapy by magnifying ... Nanobiotix SA is a clinical-stage biotechnology company that focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. It develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its lead product candidate is NBTXR3, a preclinical research program for cancer immunotherapies. Show more

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Preparations

Website

www.nanobiotix.com

Headquarters

Paris, Paris, Fra

Founded

1970

Nanobiotix SA is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker NBTX. The last closing price for Nanobiotix was $5.35. Over the last year, Nanobiotix shares have traded in a share price range of $ 0.00 to $ 0.00.

Nanobiotix currently has 47,133,000 shares outstanding. The market capitalization of Nanobiotix is $198.90 million. Nanobiotix has a price to earnings ratio (PE ratio) of -5.01.

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	0	0	0	0	0	0	0	DR
4	0	0	0	0	0	0	0	DR
12	0	0	0	0	0	0	0	DR
26	0	0	0	0	0	0	0	DR
52	0	0	0	0	0	0	0	DR
156	0	0	0	0	0	0	0	DR
260	0	0	0	0	0	0	0	DR

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
SHMDSCHMID Group NV	$ 5.60 (40.00%)	596
KAKineta Inc	$ 0.62 (21.69%)	4.84M
EMKREMCORE Corporation	$ 1.0099 (17.29%)	162.01k
MODDModular Medical Inc	$ 1.8658 (13.77%)	357
KITTNauticus Robotics Inc	$ 0.216 (12.50%)	3.07M
KAVLKaival Brands Innovations Group Inc	$ 4.5709 (-23.31%)	1.16M
OTRKOntrak Inc	$ 0.2053 (-17.35%)	5.33k
SPECSpectaire Holdings Inc	$ 0.37 (-13.93%)	23.07k
APVOAptevo Therapeutics Inc	$ 0.67 (-12.73%)	203.82k
VIRIVirios Therapeutics Inc	$ 0.21 (-11.84%)	196.24k
NDRAENDRA Life Sciences Inc	$ 0.11435 (10.38%)	33.13M
CRKNCrown Electrokinetics Corporation	$ 0.0618 (5.82%)	17.01M
KAKineta Inc	$ 0.62 (21.69%)	4.84M
NVDANVIDIA Corporation	$ 131.83 (-0.04%)	3.9M
GOEVCanoo Inc	$ 1.88 (4.44%)	3.74M

Monksdream

Monksdream 2 months ago

NBTX 10Q due 4/3

Monksdream

Monksdream 3 months ago

Monksdream

Monksdream 11 months ago

Nanobiotix SA NASDAQ: NBTX

GoSymbol lookup
Health Care : Biotechnology | Small Cap Value | Based in FranceCompany profile
Nanobiotix SA is a France-based nanomedicine company. The Company designs and manufactures nanoparticles that safely enhance the efficacy of radiation therapy in the treatment of cancer. It develops new tools for cancer that utilize a physical mode of action at the cellular level of the cancer cell. The Company's NanoXray technology comprises three products. Local treatment (surgery and radiotherapy) provides potential cure and gives the systemic treatment a better chance to life expectancy. NanoXray products are developed for the efficacy of radiotherapy in the tumor cell. Nanobiotix is a spin-off of the State University of New York (SUNY) at Buffalo.
This security is an American depositary receipt
ADR Fees

Monksdream

Monksdream 11 months ago

July 10, 2023
4:21 am ET
*Nanobiotix shares are trading higher after the company entered into a license agreement with Janssen Pharmaceutical for global co-development and commercialization of NBTXR3.
Benzinga
2:19 am ET
*Nanobiotix Enters License Agreement With Janssen Pharmaceutical For Worldwide Co-Development And Commercialization Of Potential First-In-Class Radioenhancer NBTXR3
Benzinga
Nanobiotix SA NASDAQ: NBTX

GoSymbol lookup
Health Care : Biotechnology | Small Cap Value | Based in FranceCompany profile
Nanobiotix SA is a France-based nanomedicine company. The Company designs and manufactures nanoparticles that safely enhance the efficacy of radiation therapy in the treatment of cancer. It develops new tools for cancer that utilize a physical mode of action at the cellular level of the cancer cell. The Company's NanoXray technology comprises three products. Local treatment (surgery and radiotherapy) provides potential cure and gives the systemic treatment a better chance to life expectancy. NanoXray products are developed for the efficacy of radiotherapy in the tumor cell. Nanobiotix is a spin-off of the State University of New York (SUNY) at Buffalo.
This security is an American depositary receipt
ADR Fees

Delayed Upgrade Clock

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions